View Latest Issue
Biologic disease-modifying antirheumatic drugs (DMARDs) were found to reduce absenteeism and increase productivity in a large meta-analysis of patients with arthritis, suggesting that these economic benefits may go a long way toward balancing the high cost of these drugs.
A study presented at the 2015 annual meeting of the International Society for Pharmaco­economics and Outcomes Research documented the steep risk in cost of treatment of psoriatic arthritis (PsA) with biologics.
Fatigue is a frequent problem for people with rheumatoid arthritis (RA), and contributes to disease-related disability.
Hydroxychloroquine should not be routinely given to patients with mild to moderate pain associated with osteoarthritis (OA) of the hand, according to the results of a randomized, double-blind, placebo-controlled, multicenter study.
In the first study of the link between ankylosing spondylitis (AS) and epigenetic factors, investigators found an association between smoking, methylation status, and radiographic disease progression.
Exposure to biologics around the time of conception does not appear to have negative effects on neonates, according to data from the German biologics RABBIT (Rheumatoid Arthritis Observation of Biologic Therapy) registry.
Triple therapy with conventional disease-modifying antirheumatic drugs (DMARDs) can achieve sustained remission in approximately 1 in 4 patients with early rheumatoid arthritis (RA).
Tick tock tick tock: that sound that’s getting impossible to ignore is the clock ticking down to 12:01 am on Thursday, October 1, 2015, when the new International Classification of Diseases, 10th Edition, Clinical Modification/Procedure Coding System (ICD-10 CM/PCS) takes effect.
A paper by Hernandez and colleagues recently published in the Journal of Arthroplasty blames the Medicare 3-day rule for lengthier hospital stays among some patients with total knee arthroplasty (TKA) compared with others.
The Centers for Medicare & Medicaid Services (CMS) took the first step toward the Merit-based Incentive Payment System (MIPS) on July 8 with the release of a proposed rule on payment policies and rates, as well as quality provisions, under the Medicare Physician Fee Schedule (PFS).
Page 1 of 3
Results 1 - 10 of 21
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology